“I'm [holding / not adding] until I see what the FDA feedback means for a filing.”
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
CMPX is trading below cash with $180M cash against $147M market cap and 34 months of runway, providing downside protection. An ESMO oral presentation on Oct 24 and FDA feedback on a biliary-tract-cancer therapy create a near-term catalyst, though the recent SEC feedback has caused uncertainty.
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
ANNX is watching for the Phase 3 topline for ARCHER II, a potential first-in-class geographic-atrophy drug showing vision protection rather than slowing progression. With 89% implied volatility to January and an insider officer buying $100K in late September, the upside binary is substantial.
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
HUMA is presenting Phase 3 data at Kidney Week this week for a dialysis-access therapy already on market with accelerating hospital adoption. Despite a low share price and tight runway, the near-term data readout and commercial momentum provide a near-term catalyst.
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
RZLT has Phase 3 topline data expected mid-December for a rare disease program with a tiny trial and pre-BLA recommendation. The $352M cap and 24-month runway provide cushion, but Phase 3 readouts lack the predictable runup pattern of PDUFA catalysts.
At post $3.70·Now $3.92+6.0% since postedas of Oct 22, 12:16 PM ET
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
PYPD has a Nov 28 PDUFA for a surgical-site-infection prevention therapy with EMA validation and positive data at IDWeek this week. At $99M cap with minimal short and low implied volatility, the binary appears underappreciated relative to the catalyst window.
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
VNDA is 52 days from a Dec 12 PDUFA in the historical runup window, with positive Phase 3 data in late September. Despite recent underperformance, the market has historically underpriced Vanda news; the stock sits at $4.04 with strong cash runway of 14 months.
At post $4.01·Now $4.07+1.4% since postedas of Oct 21, 12:15 PM ET
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
CAPR has a Nov 22 PDUFA but the AdCom voted against the drug and the data hasn't changed. The November options chain prices risk more accurately than December, reflecting the binary ahead, though the stock has underperformed despite positive Phase 3 news.
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
SVRA is 32 days from a Nov 22 PDUFA with 42% float short and 17 days to cover. The stock is in the window where historical runups favor entry, and the short squeeze dynamics provide tailwind, though FDA extension suggests caution.
At post $4.67·Now $4.670.0% since postedas of Oct 21, 4:46 PM ET
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Ameluz PDT for superficial basal cell (expanding from actinic keratosis approval) cleared 65.5% vs 4.8% in pivotal trial, with PDUFA Sep 28. High approval probability on paper, but $21M market cap with only ~$5M liquidity and minimal options chain create execution and sizing constraints.
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Drug candidate has priority review and accelerated approval requested with FDA 60-day filing acceptance window, triggering Q4 news cycle. $41M cap against $65M cash is below book value, but short interest surged to 54% of float and 7 months runway create dilution risk before approval payoff.
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
COMPANION-002 Phase 2 met primary response rate endpoint (17.1% vs 5.3%, PFS HR 0.44) but missed overall survival (8.9 vs 9.4 months, HR 1.05, p=0.78). Author flags control-arm crossover as confound; ESMO presentation Oct 23 will enable peer scrutiny of the shortfall.
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Azenosertib (rapid oral) for platinum-resistant ovarian cancer showed ~35% response rate in Cyclin E1-positive patients, with DENALI overall survival data at ESMO Oct 23. Author held at $4.84 in August; down 18% to $3.99 with ±75% implied volatility.
At post $4.03·Now $2.43-39.8% since postedas of Oct 21, 12:15 PM ET
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Bamzireotide navoxetan, an alpha emitter for neuroendocrine tumours, has dosed 76 patients in Phase 1/2a with updated data at ESMO Oct 23. $237M cash against $357M cap provides 33 months runway and full Phase 3 funding, making this author's favourite of three ESMO catalysts despite 24% short interest with slow 18-day cover.
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
ARCHER II Phase 3 in geographic atrophy (630+ patients, 2:1 vs sham) targeting vision protection via preventing 15-letter loss—a first if successful, as approved GA drugs only slow lesion growth. Topline due 2H 2026, with strong insider activity and implied volatility around ±96%, but 12.5 months runway creates execution risk if data slips.
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
Imsidolimab (IL-36R antibody) for generalized pustular psoriasis achieved 53% skin clearance by week 4 vs 13% placebo on single IV dose in NEJM-published GEMINI trial, with PDUFA Dec 12. $328M cap and $170M liquidity support potential third approval in twelve months, though low market sentiment reflects past pipeline disappointments rather than data weakness.
At post $5.33·Now $4.07-23.7% since postedas of Oct 21, 12:15 PM ET
“Watching, sized as small speculative position in August”
10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.
FDA extended the PDUFA decision to Nov 22 instead of August ruling, accepting a narrowed indication to upper limb function based on amended BLA. With $544M cap, $238M cash, and 22 months runway, the company has no near-term liquidity pressure, though the AdCom still voted against the drug and outcome remains binary.
10 penny biotechs I'm watching for August 2026, and adding slowly
Investview is a below-cash biotech name but the author downrates it versus peers: biotech funds trimmed 35% last quarter and insiders have been selling, signaling weak conviction despite the technical setup.
10 penny biotechs I'm watching for August 2026, and adding slowly
Zentalis Pharmaceuticals' azenosertib (WEE1 inhibitor) has Oct 2023 data in platinum-resistant ovarian cancer. Options pricing at ±106% implied move suggests elevated volatility; the company carries sufficient runway to reach and beyond the catalyst.
At post $4.95·Now $2.43-51.0% since postedas of Oct 21, 12:15 PM ET
10 penny biotechs I'm watching for August 2026, and adding slowly
Zura Oncology's tibulizumab in hidradenitis has topline data expected this quarter. The stock shows 8-fund accumulation (72% last quarter), insider buying, and ~33 months of cash runway, creating a favorable setup for a volatile move on near-term clinical readout.
At post $5.64·Now $4.13-26.8% since postedas of Oct 22, 9:00 AM ET
10 penny biotechs I'm watching for August 2026, and adding slowly
Compass Therapeutics' tovecimig (DLL4 x VEGF-A bispecific) has Oct 2024 data in biliary tract cancer. The company carries 31 months of runway, 41% short float, and insider officer purchases; structural setup mirrors other small-float, well-funded biotech volatility plays with dated catalysts.